Your browser doesn't support javascript.
loading
Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease.
Dowling, Gavin P; Keelan, Stephen; Cosgrove, Nicola S; Daly, Gordon R; Giblin, Katie; Toomey, Sinead; Hennessy, Bryan T; Hill, Arnold D K.
Afiliación
  • Dowling GP; Medical Oncology Lab, Department of Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland. gavindowling@rcsi.com.
  • Keelan S; The Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland. gavindowling@rcsi.com.
  • Cosgrove NS; The Department of Surgery, Beaumont Hospital, Dublin, Ireland. gavindowling@rcsi.com.
  • Daly GR; The Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Giblin K; The Department of Surgery, Beaumont Hospital, Dublin, Ireland.
  • Toomey S; The Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Hennessy BT; The Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Hill ADK; The Department of Surgery, Beaumont Hospital, Dublin, Ireland.
Breast Cancer Res Treat ; 2024 Aug 01.
Article en En | MEDLINE | ID: mdl-39090418
ABSTRACT

PURPOSE:

Receptor and subtype discordance between primary breast tumours and metastases is a frequently reported phenomenon. The aim of this article is to review the current evidence on receptor discordance in metastatic breast cancer and to explore the benefit of performing a repeat biopsy in this context.

METHODS:

Searches were undertaken on PubMed and Clinicaltrials.gov for relevant publications and trials.

CONCLUSION:

The current guidelines recommend offering to perform a biopsy of a metastatic lesion to evaluate receptor status. The choice of systemic therapy in metastatic disease is often based on the receptor status of the primary lesion. As therapeutic decision making is guided by subtype, biopsy of the metastatic lesion to determine receptor status may alter treatment. This article discusses discordance rates, the mechanisms of receptor discordance, the effect of discordance on treatment and survival outcomes, as well as highlighting some ongoing clinical trials in patients with metastatic breast cancer.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Breast Cancer Res Treat Año: 2024 Tipo del documento: Article País de afiliación: Irlanda Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Breast Cancer Res Treat Año: 2024 Tipo del documento: Article País de afiliación: Irlanda Pais de publicación: Países Bajos